News AbbVie's Humira finally faces biosimilar challenge in US AbbVie's cash-cow immunology product Humira has its first biosimilar competition in the US market with the launch of Amgen's copycat product Amjevita, several years after
News Amjevita, first Humira biosimilar approved – but no launch y... Amgen's biosimilar is ready to go, but AbbVie believes it can delay until 2022
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face